Log In Sign up
The largest database of trusted experimental protocols

Anti rps6 phospho ser235 236

Manufactured by Cell Signaling Technology
Visit Supplier
Sourced in United States

Anti-rpS6 phospho-Ser235/236 is a reagent that detects phosphorylation of the ribosomal protein S6 (rpS6) at serine residues 235 and 236. It is a tool used in research applications to study the phosphorylation status of rpS6, which is involved in cell growth and proliferation signaling pathways.

Automatically generated - may contain errors

Lab products found in correlation

Anti hif 1α, by BD (3 mentions) Anti β actin, by Cell Signaling Technology (3 mentions) Cycloheximide (chx), by Merck Group (2 mentions) Insulin, by Merck Group (2 mentions) Anti 4e bp1 phospho ser65 and thr36 45, by Cell Signaling Technology (2 mentions) Anti stat3 ser727 and tyr705, by Cell Signaling Technology (2 mentions) Dimethyloxallyl glycine dmog, by R&D Systems (2 mentions) Anti eif4e, by Cell Signaling Technology (2 mentions) Anti ha, by Roche (2 mentions) Pf 4708671, by Merck Group (2 mentions) 5 15 dpp, by Merck Group (2 mentions) Anti myc, by Cell Signaling Technology (2 mentions) Flll31, by Merck Group (2 mentions) Anti rheb, by Santa Cruz Biotechnology (2 mentions) Rapamycin, by Merck Group (1 mentions) Jsh 23, by Merck Group (1 mentions) Anti tsc2, by Cell Signaling Technology (1 mentions) Bnip3, by Cell Signaling Technology (1 mentions) Ref 1, by Cell Signaling Technology (1 mentions) Vegfa, by Cell Signaling Technology (1 mentions)

Spelling variants of this product

Anti-RPS6 (28 citations) Phospho-RPS6 (12 citations) Phospho-RPS6 (Ser235/236) (10 citations) Anti-phospho-RPS6 (7 citations) RPS6) (Ser235/236, (2 citations)

3 protocols using anti rps6 phospho ser235 236

1

Signaling Pathway Regulation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Anti-TSC2, anti-STAT3 phospho-Ser727 and Tyr705, Ref-1, Rel-A phospho-Ser365, anti-β-actin, VEGF-A, BNIP3, and anti-rpS6 phospho-Ser235/236 were obtained from Cell Signaling Technology (Danvers, MA, USA). Anti-HIF-1α was purchased from BD Transduction Laboratories (Oxford, UK). Rapamycin, FL3331, and JSH23 were bought from Merck (Darmstadt, Germany), and KU-0063794 was purchased from Chemquest Ltd. (Cheshire, UK), while APX3330, APX2009, APX2011, and RN7-58 were obtained from Apexian Pharmaceuticals (Indianapolis, IN, USA). Unless stated otherwise, all other lab chemicals were obtained from Merck.
Champion J.D., Dodd K.M., Lam H.C., Alzahrani M.A., Seifan S., Rad E., Scourfield D.O., Fishel M.L., Calver B.L., Ager A., Henske E.P., Davies D.M., Kelley M.R, & Tee A.R. (2022). Drug Inhibition of Redox Factor-1 Restores Hypoxia-Driven Changes in Tuberous Sclerosis Complex 2 Deficient Cells. Cancers, 14(24), 6195.
+ Open protocol
+ Expand
2

Intracellular Signaling Pathway Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Anti-myc, anti-rpS6 phospho-Ser235/236, anti-eIF4E, anti-4E-BP1 phospho-Ser65 and Thr36/45, anti-STAT3 Ser727 and Tyr705, and anti-β-actin antibodies were obtained from Cell Signalling Technology. Anti-Rheb was obtained from Santa Cruz (Heidelberg, Germany), anti-HA was obtained from Roche (Hertfordshire, UK), and Anti-HIF-1α was obtained from BD transduction laboratories (Oxford, UK). Rapamycin was obtained from Calbiochem (Nottingham, UK). Dimethyloxallyl Glycine (DMOG) was purchased from R & D systems (Minneapolis, USA). KU-0063794 was purchased from Chemquest Ltd. (Cheshire, UK). Cycloheximide, insulin, PF-4708671, 5,15-DPP, FLLL31 and all other general lab chemicals were obtained from Sigma-Aldrich unless otherwise stated.
Dodd K.M., Yang J., Shen M.H., Sampson J.R, & Tee A.R. (2014). mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene, 34(17), 2239-2250.
+ Open protocol
+ Expand
3

Intracellular Signaling Pathway Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Anti-myc, anti-rpS6 phospho-Ser235/236, anti-eIF4E, anti-4E-BP1 phospho-Ser65 and Thr36/45, anti-STAT3 Ser727 and Tyr705, and anti-β-actin antibodies were obtained from Cell Signalling Technology. Anti-Rheb was obtained from Santa Cruz (Heidelberg, Germany), anti-HA was obtained from Roche (Hertfordshire, UK), and Anti-HIF-1α was obtained from BD transduction laboratories (Oxford, UK). Rapamycin was obtained from Calbiochem (Nottingham, UK). Dimethyloxallyl Glycine (DMOG) was purchased from R & D systems (Minneapolis, USA). KU-0063794 was purchased from Chemquest Ltd. (Cheshire, UK). Cycloheximide, insulin, PF-4708671, 5,15-DPP, FLLL31 and all other general lab chemicals were obtained from Sigma-Aldrich unless otherwise stated.
Dodd K.M., Yang J., Shen M.H., Sampson J.R, & Tee A.R. (2014). mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene, 34(17), 2239-2250.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!